| DEALFLOWUPDATE Issue #19. Friday, October 12 |
Hello everyone, As we conduct our diligence for a deal, one of the earliest items is an in-depth evaluation of the proposed mechanism of action. We extensively review what has been proven so far and the feasibility of the new device to make it onto the market. In addition to evaluating what the proposed applications are, we also think about additional unforseen applications as part of our platform metric. A new mechanism of action can potentially apply towards many medical and non-medical applications and, in some cases, even be the start of an entirely new trend. This brainstorming portion of our diligence feeds directly into our intellectual property workshops, where our team and our portfolio companies’ teams come together to plan out all the additional filings that should be made on their platform technology. One of the new trends that we have seen is external, sometimes non-invasive, stimulation of nerves, with the goal of accelerating existing processes such as blood flow or pain impulses. This can treat a number of conditions potentially without side effects, as the principle effectively accelerates natural healing processes. Thus, this mechanism can not just reduce pain but also improve healing. This is particularly interesting as we have seen several technologies using this principle replicate the effects of pharmaceuticals without the same potential for side effects. In addition, the regulatory and development paths are much shorter and lower risk. We’ve provided clear examples within our following Dealflow section. -Neal P.S. Our readership continues to grow! please subscribe if you’re new and continue to share with others on social media. Connect with us, we would love to hear from you! |
Dealflow Biodegradable device speeds nerve regeneration A series of recent technologies, spanning the early research to IPO phase, show the promise of such a mechanism of action. For example, recent research has produced a device that can stimulate and promote the regeneration of damaged nerves through a biodegradable, implanted device. This can be used to treat nerves damaged in trauma or even chronic conditions. Read More  Axonics Modulation Technologies readies $86M IPO On the other end of the development spectrum, a company that is preparing for an IPO, has developed a technology that stimulates the sacral nerve. This stimulation can treat a wide variety of conditions without the need for pharmaceuticals; this includes various digestive and bladder conditions. Read More  SPR Therapeutics wins $10M from the DoD Similarly, a company has developed a non-invasive nerve stimulation technology that can address chronic and possible acute pain. This has significant potential, particularly in addressing pain without a opiod solution. Read More  Xtreem Pulse’s Rapid Pulse Compressor Gains CE Mark In the same theme of stimulating natural processes, a recent technology can stimulate the oxygen and nutrient flow into cells. This is, again, through a device and without pharmaceutical modulation. Such stimulation can promote healing in those with cardiovascular disease, or even enhance conditions in already healthy individuals. Read More Spotlight  #PortfolioHighlights We have highlighted Optina Dx recently but are excited to share a congratulations to the Optina team in their most recent funding close. Press ReleaseOptina Diagnostics Inc. has closed a $4 million new round of financing led by Zoic Capital with participation of Desjardins Capital, DigitalDx Ventures, Pallasite Ventures, Barney Pell, Barney Pell’s AngelList Syndicate, Advisors.fund and Hike Ventures.Optina Diagnostics, a technology developer for early detection of Alzheimer through the use of Artificial Intelligence (AI) and Spectral Retinal Imaging, intend to use new funding to scale up its clinical development and accelerate its growth and market readiness. ShareTweetForward What We’re ReadingFRB Transformational Medicine: It Starts And Ends With Patients WIR The Human Cell Atlas Is Biologists’ Latest Grand Project WIR To An AI, Every Eye Tells A Story PB Following a strong quarter, venture capital is on track for another historic year [datagraphic] Connect With Zoic Capital |
| The Biweekly Dealflow Update, curated by the team at Zoic Capital. |
Recommended For You
Neuralink and the Long Path to Approval
Neuralink and the Long Path to Approval
zoicaccountSeptember 11, 2021
As 2021 begins, we reflect on scientific advancements in 2020 spurred by the COVID-19 crisis
As 2021 begins, we reflect on scientific advancements in 2020 spurred by the COVID-19 crisis
zoicaccountJanuary 31, 2021
COVID-19, Alzheimer’s, and Cancer Testing
COVID-19, Alzheimer’s, and Cancer Testing
zoicaccountDecember 7, 2020